Article
Medicine, Research & Experimental
Peiling Xie, Rui An, Shibo Yu, Jianjun He, Huimin Zhang
Summary: This study identified and validated five heterogeneous immune subtypes among ER+/PR-/HER2- breast cancer, each with distinct cellular and molecular characteristics, potential immune escape mechanisms, genomic drivers, and clinical outcomes. An immune-cold subtype had a poorer prognosis, while an immune-hot subtype showed the highest infiltration of immune cells and a better prognosis. The analysis revealed a complex immune landscape with discrete clusters and a continuous spectrum.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Article
Oncology
Jose P. Leone, Noah Graham, Julieta Leone, Sara M. Tolaney, Bernardo A. Leone, Rachel A. Freedman, Michael J. Hassett, Carlos T. Vallejo, Eric P. Winer, Nancy U. Lin, Nabihah Tayob
Summary: This study developed a tool called "ESTIMATE-TN" to assess the risk of breast cancer-specific mortality (BCSM), non-BCSM, and all-cause mortality in non-metastatic triple-negative breast cancer (TNBC) patients. The tool allows input of patient and tumor characteristics and provides a nonparametric estimate of cumulative risks using Gray's subdistribution method.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Ingrid Espinoza, Chandra Kurapaty, Cheol-Hong Park, Travis Vander Steen, Celina G. Kleer, Elizabeth Wiley, Alfred Rademaker, Elisabet Cuyas, Sara Verdura, Maria Buxo, Carol Reynolds, Javier A. Menendez, Ruth Lupu
Summary: Triple-negative/basal-like breast cancer is characterized by aggressive biological features. Targeting CCN1/CYR61 may have therapeutic value in suppressing the biological aggressiveness of this type of breast cancer.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Review
Oncology
Filippo Borri, Annarita Granaglia
Summary: This review discusses the pathological aspects, molecular markers, and new frontier of immunotherapy in triple-negative breast cancer (TNBC), emphasizing the importance of histological diagnosis on clinical outcomes.
SEMINARS IN CANCER BIOLOGY
(2021)
Article
Oncology
Min Wu, Keyu Yuan, Shuzhen Lyu, Yanping Li
Summary: This study identified GAL as a potential immune signature for predicting the immune response in early basal-like/triple-negative BC. The relationship between GAL and tumor immune cell infiltration, especially CD8(+) T cells, was confirmed. GAL may serve as a marker for response to immune checkpoint therapy in early basal-like/triple-negative BC.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Nindo B. Punturi, Sinem Seker, Vaishnavi Devarakonda, Aloran Mazumder, Rashi Kalra, Ching Hui Chen, Shunqiang Li, Tina Primeau, Matthew J. Ellis, Shyam M. Kavuri, Svasti Haricharan
Summary: Resistance to endocrine treatment in ER+ breast cancer patients is linked to activation of HER2 due to loss of mismatch repair, and inhibiting HER2 restores sensitivity to treatment. Loss of MutL and upregulation of HER2 are associated with sensitivity to HER inhibitors in ER+/HER2(-) patients.
NATURE COMMUNICATIONS
(2021)
Article
Multidisciplinary Sciences
Hirotoshi Soyama, Miki Nishio, Junji Otani, Toshiko Sakuma, Shintaro Takao, Shigeo Hara, Takaaki Masuda, Koshi Mimori, Shinya Toyokuni, John P. Lydon, Kazuwa Nakao, Hiroshi Nishina, Takumi Fukumoto, Tomohiko Maehama, Akira Suzuki
Summary: Breast cancer is the most common malignancy in women, and basal-like breast cancer (BLBC) is the most aggressive subtype. The Hippo-transcriptional coactivator with PDZ-binding motif (TAZ) pathway is found to be a key driver in the onset and progression of BLBC. Utilizing mouse models and human breast cancer cell lines, researchers have justified targeting the Hippo-TAZ pathway as a potential therapy for BLBC.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Review
Oncology
Xia Qiu, Tianjiao Zhao, Ran Luo, Ran Qiu, Zhaoming Li
Summary: TNBC is a subtype of breast cancer that lacks ER, PR, and HER-2 receptors. TAMs are macrophages infiltrating the tumor, derived from circulating blood mononuclear cells, and play a role in the occurrence and metastasis of TNBC, possibly serving as potential biomarkers for prognosis prediction.
FRONTIERS IN ONCOLOGY
(2022)
Review
Pathology
Fatemeh Derakhshan, Jorge S. Reis-Filho
Summary: This article introduces the heterogeneity of triple-negative breast cancer (TNBC) and discusses its histologic, molecular classifications, and genomic alterations. The article also explores the role of the tumor microenvironment in TNBC and its potential impact on therapeutic response. Understanding the biology of each TNBC subtype is essential for delivering personalized medicine to patients.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE
(2022)
Article
Oncology
Xiaoxiang Sun, Huanyin Tang, Yu Chen, Zhixi Chen, Zhiyi Hu, Zhen Cui, Yaming Tao, Jian Yuan, Yun Fu, Zhigang Zhuang, Qizhi He, Qian Li, Xianghong Xu, Xiaoping Wan, Ying Jiang, Zhiyong Mao
Summary: Sun et al. have identified USP15 as a regulator of PARP1 stability in triple-negative breast cancer and demonstrated that ER, PR, and HER2 inhibit USP15-mediated PARP1 stabilization through various mechanisms. This finding is important for understanding the mechanism of PARP1 stability in triple-negative breast cancer.
Article
Oncology
Melinda L. Telli, William J. Gradishar
Summary: The recent approval of 4 agents for metastatic HER2-positive breast cancer has expanded treatment options according to NCCN Guidelines. Immunotherapy is gaining traction in triple-negative disease, while sacituzumab govitecan and PARP inhibitors show strong utility in treatment of specific subtypes.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Article
Multidisciplinary Sciences
Nadine S. van den Ende, Marcel Smid, Annemieke Timmermans, Johannes B. van Brakel, Tim Hansum, Renee Foekens, Anita M. A. C. Trapman, Bernadette A. M. Heemskerk-Gerritsen, Agnes Jager, John W. M. Martens, Carolien H. M. van Deurzen
Summary: The study found that HER2low breast cancer is associated with a lower immune response compared to HER2- breast cancer. There were differences in survival, gene expression, and clinicopathologic features between HER2low and HER2- breast cancer.
SCIENTIFIC REPORTS
(2022)
Article
Clinical Neurology
Chen Jiaxin, Zhou Jinmei, Zhang Huiqiang, Wu Xuexue, Wang Xiaobo, Zhang Shaohua, Tai Yanhong, Jiang Zefei, Wang Tao
Summary: This study analyzed the expression levels of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2), and Ki-67 proliferation index in Chinese patients with breast cancer brain metastasis (BCBM), and found a correlation between their changes and patients' survival.
FRONTIERS IN NEUROLOGY
(2022)
Article
Biochemistry & Molecular Biology
Qiuyu Liu, Wanda van der Stel, Vera E. van der Noord, Hanneke Leegwater, Bircan Coban, Kim Elbertse, Joannes T. M. Pruijs, Olivier J. M. Bequignon, Gerard van Westen, Sylvia E. Le Devedec, Erik H. J. Danen
Summary: Hypoxia triggers HIF1 stabilization in luminal and basal A triple negative breast cancer cells. High throughput targeted RNA sequencing reveals overlapping and distinct target genes being modulated in these subtypes. Hypoxia induces phosphorylation of TAZ at Ser89 in basal A cells, leading to cytoplasmic sequestration of TAZ(Ser89). Hypoxia attenuates growth of basal A cells and diminishes the effect of verteporfin, a disruptor of YAP/TAZ-TEAD-mediated transcription.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Jennifer G. Schopp, Dogan S. Polat, Firouzeh Arjmandi, Jody C. Hayes, Richard W. Ahn, Kirbi Sullivan, Sunati Sahoo, Jessica H. Porembka
Summary: Triple-negative breast cancer is a aggressive subtype of breast cancer with distinct imaging challenges and characteristics that can mimic benign conditions.